BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
79.37
-1.03 (-1.28%)
At close: Aug 26, 2026, 4:00 PM EDT
80.14
+0.77 (0.97%)
After-hours: Aug 26, 2026, 6:29 PM EDT
BridgeBio Pharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 713.07 | 502.08 | 221.9 | 9.3 | 77.65 | 69.72 | |
Revenue Growth | 202.39% | 126.26% | 2285.27% | -88.02% | 11.38% | 745.14% |
Cost of Revenue | 39.66 | 20.96 | 3.88 | 2.45 | 3.43 | 3.11 |
Gross Profit | 673.41 | 481.11 | 218.02 | 6.86 | 74.21 | 66.6 |
Selling, General & Admin | 645.86 | 531.23 | 288.93 | 150.59 | 143.19 | 188.91 |
Research & Development | 505.38 | 451.95 | 506.46 | 455.71 | 399.46 | 451.02 |
Operating Expenses | 1,151 | 983.18 | 795.39 | 606.3 | 542.65 | 639.93 |
Operating Income | -477.82 | -502.06 | -577.37 | -599.44 | -468.44 | -573.33 |
Interest Expense | -205.9 | -178.24 | -99.29 | -81.29 | -80.44 | -46.78 |
Interest & Investment Income | 23.48 | 19.85 | 17.25 | 18.04 | 7.54 | 1.13 |
Earnings From Equity Investments | -61.58 | -72.61 | -31.18 | - | - | - |
Other Non Operating Income (Expenses) | 36.72 | 43.06 | 4.14 | -0.94 | 102.43 | 3.7 |
EBT Excluding Unusual Items | -685.11 | -690 | -686.46 | -663.64 | -438.9 | -615.28 |
Merger & Restructuring Charges | -19.97 | -21.35 | -15.33 | -7.93 | -43.77 | - |
Gain (Loss) on Sale of Investments | - | - | 8.14 | 18.31 | -8.22 | 29.91 |
Gain (Loss) on Sale of Assets | - | - | 178.32 | - | -6.26 | - |
Asset Writedown | - | - | -0.27 | - | - | -3.3 |
Other Unusual Items | 1.4 | -21.16 | -26.59 | - | 12.5 | 2.21 |
Pretax Income | -703.68 | -732.5 | -542.19 | -653.25 | -484.65 | -586.45 |
Income Tax Expense | -1.67 | 0.44 | 1.15 | - | - | - |
Earnings From Continuing Operations | -702.02 | -732.94 | -543.35 | -653.25 | -484.65 | -586.45 |
Minority Interest in Earnings | 10.15 | 8.01 | 7.59 | 10.05 | 3.47 | 23.92 |
Net Income | -691.87 | -724.93 | -535.76 | -643.2 | -481.18 | -562.54 |
Net Income to Common | -691.87 | -724.93 | -535.76 | -643.2 | -481.18 | -562.54 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 194 | 192 | 186 | 163 | 147 | 144 |
Shares Outstanding (Diluted) | 194 | 192 | 186 | 163 | 147 | 144 |
Shares Change | 2.29% | 2.93% | 14.30% | 10.39% | 2.16% | 22.34% |
EPS (Basic) | -3.57 | -3.78 | -2.88 | -3.95 | -3.26 | -3.90 |
EPS (Diluted) | -3.57 | -3.78 | -2.88 | -3.95 | -3.26 | -3.90 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -435.39 | -447.01 | -521.66 | -529.03 | -424.32 | -511.18 |
Free Cash Flow Per Share | -2.24 | -2.33 | -2.80 | -3.25 | -2.88 | -3.54 |
Gross Margin | 94.44% | 95.83% | 98.25% | 73.71% | 95.58% | 95.53% |
Operating Margin | -67.01% | -100.00% | -260.19% | -6443.56% | -603.28% | -822.38% |
Profit Margin | -97.03% | -144.39% | -241.44% | -6913.92% | -619.70% | -806.90% |
Free Cash Flow Margin | -61.06% | -89.03% | -235.08% | -5686.62% | -546.46% | -733.23% |
EBITDA | -472.75 | -496.63 | -571.29 | -592.95 | -461.67 | -567.49 |
EBITDA Margin | -66.30% | -98.91% | -257.45% | - | - | - |
D&A For EBITDA | 5.07 | 5.43 | 6.08 | 6.49 | 6.77 | 5.84 |
EBIT | -477.82 | -502.06 | -577.37 | -599.44 | -468.44 | -573.33 |
EBIT Margin | -67.01% | -100.00% | -260.19% | - | - | - |
Revenue as Reported | 713.07 | 502.08 | 221.9 | 9.3 | - | - |
Advertising Expenses | - | 110.1 | 21.5 | - | - | - |